NOT-CA-22-110: Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

Notice Number:

NOT-CA-22-110

Key Dates

Release Date:

July 14, 2022

Estimated Publication Date of Funding Opportunity Announcement:

August 17, 2022

First Estimated Application Due Date:

October 17, 2022

Earliest Estimated Award Date:

July 03, 2023

Earliest Estimated Start Date:

July 03, 2023

Related Announcements

PAR-19-158 - Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

NOT-CA-22-111 - Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)

Issued by

National Cancer Institute (NCI)

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The National Cancer Institute (NCI) intends to reissue PAR-19-158 Bioengineering Research Grants (BRG; R01 Clinical Trial Not Allowed) with additional partnering NIH Institutes and Centers, to encourage collaborations between the life and physical sciences to foster the development of innovative technology, model, technique, design, or method that has the potential for significant impact on biomedical research by infusing principles and concepts from the quantitative science.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The Funding Opportunity Announcement (FOA) is expected to be published in late Summer 2022 with an anticipated application due date in Fall 2022. This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

This Notice encourages biomedical and/or bioengineering researchers to consider applying for this FOA. In addition, collaborative investigations combining expertise in biomedical, bioengineering, health care delivery, physics, computer science etc. will be encouraged and these investigators should also begin considering applying for this FOA. Among the areas of research encouraged in this initiative are preclinical and clinical research and basic biology studies examining the mechanisms that underlie the effects of conditions and diseases within the missions of participating NIH Institutes and Centers, as well as research designed to improve the translation of existing knowledge of strategies for the prevention and treatment of these diseases.

Funding Information

Estimated Total Funding

TBD

Expected Number of Awards

Estimated Award Ceiling

Up to $500,000 in direct cost

Primary Assistance Listing Number(s)

TBD

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Miguel R. Ossandon, Ph.D.

National Cancer Institute (NCI)

240-276-5714

Email: ossandom@mail.nih.gov

Sahana N. Kukke, Ph.D.
Telephone: 301-496-1447
National Institute of Neurological Disorders and Stroke (NINDS)
sahana.kukke@nih.gov